Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaxCyte Regulatory News (MXCT)

  • There is currently no data for MXCT

AIM Block Admission Return / Total Voting Rights

20 Feb 2020 18:18

RNS Number : 6728D
MaxCyte, Inc.
20 February 2020
 

SCHEDULE 6

AIM BLOCK ADMISSION RETURN / TOTAL VOTING RIGHTS

 

Please ensure the entries on this return are typed

 

a. Name of company

 

MaxCyte, Inc.

 

b. Name of scheme(s)

 

MaxCyte Long Term Incentive Plan

 

c. Period of return:

 

From 17 November 2018 To 20 February 2020

 

d. Number and class of securities not issued under scheme

 

415,759 ordinary shares of common stock of $0.01 each

 

e. Number of shares issued under scheme during period

 

96,496 ordinary shares of common stock of $0.01 each

 

f. Balance under the scheme not yet issued at the end of the period.

 

319,263 ordinary shares of common stock of $0.01 each

 

g. Number and class of share(s) (amount of stock / debt securities) originally listed and the date of admission; If additional blocklisting application have been made, under this scheme, since the original listing application please also state the number of shares and the date(s) of admission.

 

1,000,000 ordinary shares of common stock of $0.01 each on 5 May 2017

 

Please confirm your total issued share capital as at the end of this period.

(If you hold any shares in Treasury state the figure separately);

 

57,403,583 (51,444,847 MXCT.L and 5,958,736 MXCS.L)

 

 

Treasury shares (if applicable) ………Nil………….

 

h. Contact name and telephone number for queries;

 

Doug Doerfler, Chief Executive Officer

Ron Holtz, Chief Financial Officer

+1 301 944 1660

 

Date

 

20 February 2020

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCURRWRRNUUUAR
Date   Source Headline
16th Jul 20187:00 amRNSTrading Update
11th Jun 20187:00 amRNSMaxCyte & NIH enter CRADA for Sickle Cell Disease
21st May 20187:00 amRNSPreclinical Results at ASGCT Annual Meeting
30th Apr 20187:00 amRNSNotice of AGM and Annual Report
25th Apr 20187:00 amRNSCMO Appointment
4th Apr 20187:00 amRNSFinal Results for Year Ended 31 December 2017
15th Mar 20187:00 amRNSNotice of Full Year Results
28th Feb 20185:00 pmRNSDirector/PDMR Shareholding
15th Feb 20187:00 amRNSGrant of Options
13th Feb 20187:00 amRNSDr Richard Douglas Joins MaxCyte Board
1st Feb 20184:06 pmRNSBlock listing Interim Review
23rd Jan 20181:32 pmRNSTotal Voting Rights
22nd Jan 20187:00 amRNSTrading Update
12th Jan 20185:13 pmRNSTotal Voting Rights
30th Nov 20173:26 pmRNSTotal Voting Rights
31st Oct 201712:47 pmRNSResult of AGM
16th Oct 20177:00 amRNSDeclaration of Audit Remuneration
5th Oct 20176:32 pmRNSHolding(s) in Company
5th Oct 20176:31 pmRNSHolding(s) in Company
28th Sep 20175:15 pmRNSNotice of AGM
19th Sep 20177:00 amRNSInterim Results
25th Aug 20177:00 amRNSNotice of Half Year Results
20th Jul 20176:02 pmRNSGrant of Options
12th Jul 20177:00 amRNSTrading Update
6th Jun 20177:00 amRNSResearch & Development Agreement with NIAID
31st May 20174:30 pmRNSTotal Voting Rights
2nd May 20171:42 pmRNSBlock Listing Application
25th Apr 20176:27 pmRNSHolding(s) in Company
25th Apr 20177:00 amRNSPresentation of Positive Preclinical Data
20th Apr 20176:00 pmRNSResult of Special Meeting and Issue of Equity
13th Apr 20171:00 pmRNSNotice of AGM and 2016 Annual Report and Accounts
31st Mar 201712:40 pmRNSResults of Placing
31st Mar 20177:00 amRNSProposed Placing to raise up to approx. £20.0m
20th Mar 20177:00 amRNSFull Year Results
14th Mar 20177:00 amRNSCRISPR THERAPEUTICS/CASEBIA COMMERCIAL LICENSE
2nd Mar 20177:00 amRNSMaxCyte to Present Pre-Clinical CARMA Data at AACR
1st Mar 20177:00 amRNSNotice of Full Year Results
24th Jan 20177:00 amRNSTrading Update
12th Jan 20177:00 amRNSStudy Published in Science Translational Medicine
3rd Jan 20172:49 pmRNSIssue of Equity from exercise of Share Options
21st Dec 20167:00 amRNSMaxCyte Announces Collaboration to Advance CARMA
6th Dec 20169:34 amRNSIssue of Equity from exercise of Share Options
27th Oct 20167:00 amRNSResult of Annual General Meeting
21st Oct 20167:43 amRNSDirector/PDMR Shareholding
28th Sep 20166:00 pmRNSGrant of Options
27th Sep 20167:00 amRNSFinancial Results for Six Months ended 30 June 16
19th Sep 20165:00 pmRNSNotice of AGM
6th Sep 20167:00 amRNSMaxCyte Bolsters Distributor Network in Asia
6th Sep 20167:00 amRNSNotice of Interim Results
12th Jul 20167:00 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.